CYTEK(US:CTKB) Newsfilter·2025-01-15 13:00Core Viewpoint - Cytek Biosciences, Inc. anticipates a revenue growth of approximately 4% for the full year 2024, with preliminary revenue estimates between $200 million and $201 million, despite facing foreign exchange challenges [2][3]. Financial Performance - The expected revenue for 2024 is projected to be between $200 million and $201 million, compared to $193 million in 2023, indicating a growth of 4% [2]. - The anticipated revenue for the fourth quarter of 2024 is between $57 million and $58 million, reflecting an 11% to 13% increase from the third quarter of 2024, but a decline of 2% to flat compared to the fourth quarter of 2023 [2]. - The appreciation of the US dollar negatively impacted fourth quarter revenue by approximately $1.5 million [2]. Market Insights - Cytek's revenue in the Asia Pacific and Rest of World markets showed strong growth, although overall fourth quarter results were slightly below expectations due to currency appreciation and order delays [3]. - The company remains optimistic about its long-term potential and business strategy, highlighting a significant opportunity for its advanced cell analysis tools [3]. Upcoming Events - Cytek will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 16, 2025, providing an opportunity for investors to gain insights into the company's performance and strategy [4]. Company Overview - Cytek Biosciences specializes in cell analysis solutions, utilizing its patented Full Spectrum Profiling™ technology to deliver high-resolution and high-sensitivity analysis tools [5]. - The company's product offerings include the Cytek Aurora™ and Northern Lights™ systems, among others, aimed at providing a comprehensive suite of solutions for customers [5].